Abgent

Abgent, a WuXi AppTec company

Discovery Demands It™
Type	Public
Traded as	: WX
Industry	Biotech, Life Sciences, Manufacturing
Founded	San Diego, California, United States (2001)
Headquarters	USA
Area served	Worldwide
Products	antibodies, peptides, custom antibody services, custom peptide services, custom protein services
Number of employees	200 (2014)
Website	www.abgent.com

Abgent is a global biotechnology company based in San Diego, California, US with offices in Maidenhead, UK and Suzhou, China and distributors around the world. Abgent develops antibodies and related agents to study proteins involved in cellular function and disease. Abgent's antibodies target key areas of research including autophagy, neuroscience, cancer, stem cells and more. Abgent was acquired in 2011 by WuXi AppTec, a global pharmaceutical, biopharmaceutical, and medical device outsourcing company with operations in China and the United States.

Abgent was listed as a selected supplier in Nature Magazine,Antibody Technology, Drug Discovery Features and The Scientist's cell signaling feature. More than 1,100 peer-reviewed publications in scientific journals have cited Abgent antibody, protein, and peptide products and custom services.

As one of the world's largest manufacturers of antibodies for biological research and drug discovery, Abgent develops, produces, and sells antibodies for use in academic, biotechnological, and pharmaceutical industries. Core products are complemented by custom antibody services and custom protein services for drug discovery targets.

SUMOplot is a tool used to predict sumoylation sites, an important post-translational modification of proteins. SUMO-modified proteins contain the tetrapeptide motif B-K-x-D/E where B is a hydrophobic residue, K is the lysine conjugated to SUMO, x is any amino acid (aa), D or E is an acidic residue. Substrate specificity appears to be derived directly from Ubc9 and the respective substrate motif. SUMOplot predicts the probability for the SUMO consensus sequence (SUMO-CS) to be engaged in SUMO attachment. The SUMOplot score system is based on two criteria: first, direct amino acid match to the SUMO-CS observed and shown to bind Ubc9, and second, substitution of the consensus amino acid residues with amino acid residues exhibiting similar hydrophobicity. SUMOplot has been used in the past to predict Ubc9 dependent sites.